vs
Side-by-side financial comparison of Velocity Financial, Inc. (VEL) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
Velocity Financial, Inc. is the larger business by last-quarter revenue ($51.6M vs $34.1M, roughly 1.5× ZEVRA THERAPEUTICS, INC.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 32.8%). Velocity Financial, Inc. produced more free cash flow last quarter ($17.9M vs $5.5M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 32.3%).
Velocity Financial, Inc. is a U.S.-headquartered real estate finance company that offers specialized mortgage loan solutions primarily for residential investment properties. It partners with independent mortgage brokers nationwide, providing real estate investors with short-term bridge loans and long-term rental property financing options tailored to their operational needs.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
VEL vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $51.6M | $34.1M |
| Net Profit | $34.8M | — |
| Gross Margin | — | — |
| Operating Margin | 97.0% | 27.3% |
| Net Margin | 67.3% | — |
| Revenue YoY | 32.8% | 183.4% |
| Net Profit YoY | 67.0% | — |
| EPS (diluted) | $0.90 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $51.6M | $34.1M | ||
| Q3 25 | $49.1M | $26.1M | ||
| Q2 25 | $47.6M | $25.9M | ||
| Q1 25 | $37.5M | $20.4M | ||
| Q4 24 | $38.9M | $12.0M | ||
| Q3 24 | $35.1M | $3.7M | ||
| Q2 24 | $32.4M | $4.4M | ||
| Q1 24 | $29.5M | $3.4M |
| Q4 25 | $34.8M | — | ||
| Q3 25 | $25.4M | $-544.0K | ||
| Q2 25 | $26.0M | $74.7M | ||
| Q1 25 | $18.9M | $-3.1M | ||
| Q4 24 | $20.8M | — | ||
| Q3 24 | $15.8M | $-33.2M | ||
| Q2 24 | $14.8M | $-19.9M | ||
| Q1 24 | $17.3M | $-16.6M |
| Q4 25 | 97.0% | 27.3% | ||
| Q3 25 | 72.1% | 15.9% | ||
| Q2 25 | 71.3% | -274.5% | ||
| Q1 25 | 71.7% | -26.3% | ||
| Q4 24 | 82.5% | -128.0% | ||
| Q3 24 | 60.6% | -739.0% | ||
| Q2 24 | 61.3% | -534.8% | ||
| Q1 24 | 78.8% | -598.1% |
| Q4 25 | 67.3% | — | ||
| Q3 25 | 51.7% | -2.1% | ||
| Q2 25 | 54.6% | 288.7% | ||
| Q1 25 | 50.4% | -15.2% | ||
| Q4 24 | 53.5% | — | ||
| Q3 24 | 45.1% | -899.2% | ||
| Q2 24 | 45.6% | -447.9% | ||
| Q1 24 | 58.5% | -485.3% |
| Q4 25 | $0.90 | — | ||
| Q3 25 | $0.65 | $-0.01 | ||
| Q2 25 | $0.69 | $1.21 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.56 | — | ||
| Q3 24 | $0.44 | $-0.69 | ||
| Q2 24 | $0.42 | $-0.48 | ||
| Q1 24 | $0.49 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.1M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $672.5M | $154.7M |
| Total Assets | $7.4B | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.1M | $62.4M | ||
| Q3 25 | $99.0M | $54.4M | ||
| Q2 25 | $79.6M | $47.7M | ||
| Q1 25 | $51.7M | $37.3M | ||
| Q4 24 | $49.9M | $33.8M | ||
| Q3 24 | $44.1M | $54.0M | ||
| Q2 24 | $47.4M | $39.3M | ||
| Q1 24 | $34.8M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $672.5M | $154.7M | ||
| Q3 25 | $634.3M | $133.2M | ||
| Q2 25 | $597.9M | $117.2M | ||
| Q1 25 | $563.2M | $41.0M | ||
| Q4 24 | $516.9M | $39.7M | ||
| Q3 24 | $484.6M | $69.8M | ||
| Q2 24 | $471.3M | $32.5M | ||
| Q1 24 | $452.9M | $48.8M |
| Q4 25 | $7.4B | $284.7M | ||
| Q3 25 | $7.0B | $270.1M | ||
| Q2 25 | $6.5B | $256.3M | ||
| Q1 25 | $6.0B | $172.7M | ||
| Q4 24 | $5.5B | $178.1M | ||
| Q3 24 | $5.2B | $191.6M | ||
| Q2 24 | $4.9B | $144.4M | ||
| Q1 24 | $4.6B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $5.5M |
| Free Cash FlowOCF − Capex | $17.9M | $5.5M |
| FCF MarginFCF / Revenue | 34.6% | 16.1% |
| Capex IntensityCapex / Revenue | 0.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.3M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $5.5M | ||
| Q3 25 | $11.5M | $4.7M | ||
| Q2 25 | $7.7M | $-3.6M | ||
| Q1 25 | $3.5M | $-8.2M | ||
| Q4 24 | $37.8M | $-16.3M | ||
| Q3 24 | $-17.6M | $-18.1M | ||
| Q2 24 | $11.5M | $-19.1M | ||
| Q1 24 | $10.6M | $-16.2M |
| Q4 25 | $17.9M | $5.5M | ||
| Q3 25 | $11.4M | $4.2M | ||
| Q2 25 | $7.6M | $-3.8M | ||
| Q1 25 | $3.5M | $-8.3M | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $-17.6M | — | ||
| Q2 24 | $11.4M | — | ||
| Q1 24 | $10.5M | — |
| Q4 25 | 34.6% | 16.1% | ||
| Q3 25 | 23.2% | 15.9% | ||
| Q2 25 | 15.9% | -14.7% | ||
| Q1 25 | 9.2% | -40.8% | ||
| Q4 24 | 96.4% | — | ||
| Q3 24 | -50.3% | — | ||
| Q2 24 | 35.1% | — | ||
| Q1 24 | 35.8% | — |
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 0.1% | 2.1% | ||
| Q2 25 | 0.2% | 0.8% | ||
| Q1 25 | 0.2% | 0.5% | ||
| Q4 24 | 0.7% | 0.0% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.3% | 0.0% | ||
| Q1 24 | 0.1% | 0.0% |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.29× | -0.05× | ||
| Q1 25 | 0.19× | — | ||
| Q4 24 | 1.81× | — | ||
| Q3 24 | -1.11× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VEL
| Related Party | $19.3M | 37% |
| Nonrelated Party | $16.9M | 33% |
| Other | $15.4M | 30% |
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
